High precision-cut liver slice model to study cell-autonomous antiviral defense of hepatocytes within their microenvironment

Authors
Marcus Brugger, Melanie Laschinger, Sandra Lampl, Annika Schneider, Katrin Manske, Dena Esfandyari, Norbert Hüser, Daniel Hartmann, Katja Steiger, Stefan Engelhardt, Dirk Wohlleber, Percy A. Knolle

Correspondence
percy.knolle@tum.de (P.A. Knolle), marcus.brugger@tum.de (M. Brugger).

Graphical abstract

Study of complex hepatocyte intrinsic functions within their liver microenvironment

in vivo experiments

Improved method for precision cut liver slices (PCLS) for ex vivo analysis

in vitro 3D culture

Quantitative evaluation of cell intrinsic death in vulnerable hepatocytes

Highlights
- Precision-cut liver slices (PCLS) can be used to study hepatocyte-intrinsic regulation of cell death ex vivo.
- Increased induction of apoptosis is detected in PCLS from adenovirus- and LCMV-infected livers after TNF challenge ex vivo.
- Optimized protocol may enable the characterization of human hepatocyte sensitivity to apoptosis in PCLS from patients with liver diseases.

Lay summary
Virus-infected hepatocytes in vivo show an increased sensitivity towards induction of cell death signaling through the TNF receptor. Studying this hepatocyte-intrinsic antiviral immune surveillance mechanism has been hampered by the absence of model systems that reciprocate the in vivo finding of increased apoptosis of virus-infected hepatocytes challenged with TNF. Herein, we report that an optimized protocol for generation of precision-cut liver slices can be used to study this hepatocyte-intrinsic surveillance mechanism ex vivo.

https://doi.org/10.1016/j.jhepr.2022.100465
High precision-cut liver slice model to study cell-autonomous antiviral defense of hepatocytes within their microenvironment

Marcus Brugger,1,2,† Melanie Laschinger,3 Sandra Lampi,1 Annika Schneider,1 Katrin Manske,1 Dena Esfandyari,5 Norbert Hüser,3 Daniel Hartmann,3 Katja Steiger,4 Stefan Engelhardt,5 Dirk Wohlleber,1,7 Percy A. Knolle1,2,†

1Institute of Molecular Immunology and Experimental Oncology, School of Medicine, Technical University of Munich, Germany; 2Department of Internal Medicine I, School of Medicine, University Hospital Munich rechts der Isar, Technical University of Munich, Germany; 3Department of Surgery, School of Medicine, University Hospital Munich rechts der Isar; Technical University of Munich, Germany; 4Institute of Pharmacology and Toxicology, Technical University Munich, Munich, Germany; 5Institute of Pharmacology and Toxicology, Technical University of Munich, Germany; 6Institute of Pathology, Technical University of Munich, Munich, Germany

JHEP Reports 2022. https://doi.org/10.1016/j.jhepr.2022.100465

Background & Aims: Increased sensitivity towards tumor necrosis factor (TNF)-induced cell death in virus-infected hepatocytes has revealed a so far unrecognized hepatocyte-intrinsic antiviral immune surveillance mechanism, for which no in vitro or ex vivo model is available. We aimed to establish precision-cut liver slices (PCLS) as a model system to study hepatocyte-intrinsic regulation of apoptosis.

Methods: Preparation of PCLS from mouse and human liver tissue was optimized for minimal procedure-associated apoptosis. Functionality of liver cells in PCLS was characterized using extracellular flux analysis to determine mitochondrial respiration, and viral infection with recombinant adenovirus and lymphocytic choriomeningitis virus (LCMV) was used to probe for hepatocyte-intrinsic sensitivity towards apoptosis in PCLS. Apoptosis was detected by immunohistochemical staining for cleaved-caspase 3 and quantified by detection of effector caspase activity in PCLS.

Results: We established an optimized protocol for preparation of PCLS from human and mouse models using agarose-embedding of liver tissue to improve precision cutting and using organ-protective buffer solutions to minimize procedure-associated cell death. PCLS prepared from virus-infected livers showed preserved functional metabolic properties. Importantly, in PCLS from adenovirus- and LCMV-infected livers we detected increased induction of apoptosis after TNF challenge ex vivo.

Conclusion: We conclude that PCLS can be used as model system to ex vivo characterize hepatocyte-intrinsic sensitivity to cell death. This may also enable researchers to characterize human hepatocyte sensitivity to apoptosis in PCLS prepared from patients with acute or chronic liver diseases.

Keywords: TNF-induced apoptosis; precision-cut liver slices; anti-viral immunity.

Introduction

Immune effector cell populations like virus-specific T cells and natural killer cells, that recognize and kill virus-infected hepatocytes, contribute to successful immune surveillance in the liver.1 The selective elimination of virus-infected hepatocytes was considered to rely entirely on the ability of virus-specific effector cell populations to execute their killing activity. Consequently, research aiming to understand successful or failing immune surveillance against viral infection in the liver has mainly focused on studying the numbers and the breadth of effector function of virus-specific T cells.2,3 Recently it has become evident, however, that hepatocytes themselves contribute to immune surveillance by developing a unique state of responsiveness towards death signals.4 Virus-infected but not healthy hepatocytes selectively respond to tumor necrosis factor (TNF) receptor signaling with induction of caspase-induced cell death, i.e., apoptosis. This reveals the existence of hepatocyte-intrinsic antiviral surveillance that is independent of cytolytic T cell effector function and that leads to death of hepatocytes.4,5

Currently, there are no in vitro or ex vivo models in place to study the contribution and mechanistic aspects of this increased sensitivity to apoptosis in hepatocytes in liver diseases.
Hepatocytes function within their microenvironment, which may be important to sustain their metabolic and immune functions and may explain why certain functions observed in vivo are not observed in vitro in isolated primary hepatocytes. The necessity to study organ context-dependent functions of cells has been recognized as a general challenge, and has led to the development of experimental model systems in many organ-specific research fields that allow for contextual analysis of cell functions in tissues. For the liver, different 3D cell culture models have been developed, which simulate the hepatic microanatomy like liver scaffolds and facilitate the growth of different liver cell populations in defined 3D-structures. Stem cell-derived liver cells were also used to construct human liver tissue. Yet, all these approaches require sophisticated technologies. A more direct approach to generate 3D tissue models, which reflect the complexity of tissue organization, for the study of tissue context-dependent cell functions is the generation of precision-cut tissue slices. Precision-cut liver slice (PCLS) models were used in the past to explore pathophysiological mechanisms underlying chronic liver damage, and mechanisms underlying hepatic steatosis, steatohepatitis or drug metabolism. Herein, we report on an improved PCLS model that enables the ex vivo analysis of hepatocyte-intrinsic mechanisms, which determine sensitivity of virus-infected hepatocytes towards death signaling.

Materials and methods

Mouse and human liver

C57BL/6j mice were purchased from Charles River (Germany). All mice used in the experiments were maintained under specific pathogen-free conditions according to the guidelines of the Federation of Laboratory Animal Science Association. Animal experiments were approved by local authorities (ROB-55.2.2532.Vet_02-18-16). Experiments with human liver samples were approved by and performed in accordance with the regulations of the Ethics committee at the Technical University of Munich (86/17S) and the ethical guidelines of the World Medical Association Declaration of Helsinki. Informed written consent was obtained from each patient.

Preparation of PCLS

Murine livers were removed from anesthetized mice (2.5% isoflurane) and human liver tissue was obtained from patients undergoing liver resection for colorectal tumor metastasis. PCLS were generated as described here in short. After resection, liver tissue was immediately stored in the organ-preservation buffer solution custodiol® at 4°C (Köhler, Germany) and was immersed in 4% low-melting agarose. Agarose-stabilized liver tissue enabled the generation of PCLS using a vibratome Leica VT 1000S (Leica Biosystems, Germany). The freshly generated PCLS were maintained in Williams E Medium (PAN-Biotech, Germany), with gentle orbital shaking (80 times/min) at 37°C in a CO2 incubator to ensure tissue oxygenation and consistent exposure to reagents during experiments (please visit our detailed protocol for generation of PCLS in the supplementary information).

Results

Improved preparation of mouse and human PCLS

In vivo the induction of apoptosis in hepatocytes infected with a recombinant adenovirus coding for the marker genes GFP and luciferase (Ad-CMV-GL, 5x10^8 infectious units per mouse) occurred within 2 hours after TNF challenge (Fig. 1A,B). However, TNF-induced cell death after in vitro infection of hepatocytes with Ad-CMV-GL, required more than 5 hours, measured by loss of electrical impedance of the hepatocyte cell layer in a 96-well plate (Fig. 1C). Since it is not possible to isolate viable virus-infected hepatocytes for mechanistic in vitro studies of induction of cell death, we set out to establish a PCLS model that could enable the ex vivo characterization of the unique responsiveness of virus-infected hepatocytes in vivo within the liver to die by apoptosis.

We improved the generation of PCLS by stabilizing mouse and human liver tissue in a low-melting agarose to allow for gentle precision cutting of liver tissue into slices and by reducing tissue damage during this procedure through use of an organ-protective buffer solution (see detailed protocol for preparation of PCLS). Histomorphological analysis demonstrated that neither generation of PCLS nor subsequent incubation at 37°C for a period of 2 hours led to detectable cell damage in mouse and human PCLS (Fig. 1D). Consequently, we did not detect a release of lactate dehydrogenase, a marker for cell death, from PCLS after cutting or after incubation at 37°C (Fig. 1E). To confirm the absence of apoptotic cell death in the improved PCLS, we quantified induction of apoptosis by measuring cleaved-caspase 3, which is the apoptosis inducing active form of the effector caspase 3. We found very few cleaved-caspase 3-positive cells by immunohistochemistry in murine and human PCLS (Fig. 1F,G) compared to a higher number of apoptotic cells in PCLS generated by the conventional method (Fig. S1). Numbers of cleaved-caspase 3-positive hepatocytes were slightly higher in human PCLS (0.54% ± 0.27) compared to murine PCLS (0.23% ± 0.5). Taken together, these results demonstrated that the improved method for generating PCLS yielded viable liver tissue without generation of procedure-associated apoptotic cells (Fig. 1).

PCLS as ex vivo model system to study hepatocyte sensitivity to apoptosis

Establishing PCLS that did not bear high numbers of apoptotic cells allowed us to investigate whether these PCLS could be employed to study ex vivo the apoptotic response of infected hepatocytes observed in vivo. We first evaluated whether hepatocytes infected in vivo were detected in PCLS ex vivo. To this end, we generated a recombinant adenovirus coding for the fluorescence reporter gene iRFP720 (Ad-CMV-GIRO) that enables the detection of in vivo fluorescence activity of Ad-CMV-GIRO-infected hepatocytes due to the high tissue-penetration of light with high wavelength (>700 nm) emitted from iRFP720. In vivo fluorescence imaging of Ad-CMV-GIRO-infected mice demonstrated successful adenoviral transduction of the liver (Fig. 2A). Importantly, iRFP720-fluorescence was also ex vivo detected in PCLS from livers of mice infected with Ad-CMV-GIRO (Fig. 2B,C). No fluorescence signal was detected from uninfected livers in vivo or from PCLS prepared from these livers ex vivo (Fig. 2A-C). Histomorphological analysis of PCLS from infected livers compared to non-infected livers by H&E staining or staining for apoptotic cells (detection of cleaved-caspase 3) did not reveal tissue damage after infection (Fig. 2D). Taken together, these results demonstrated that virus-infected cells were present in PCLS generated from Ad-CMV-GIRO-infected liver.

Viral infection leads to rapid expression of viral genes that might cause changes in cellular metabolism. We therefore investigated whether metabolic mitochondrial activity was
different in PCLS prepared from Ad-CMV-GIRO-infected livers compared to healthy livers. There was no difference in mitochondrial respiration activity measured by extracellular flux analysis of PCLS prepared from Ad-CMV-GIRO-infected compared to healthy livers (Fig. 2E, Fig. S2). In the absence of a change in mitochondrial respiration after Ad-CMV-GIRO infection, we next characterized the response of Ad-CMV-GIRO-infected cells to TNF challenge. Strikingly, in PCLS prepared
Fig. 2. TNF mediates cell death in PCLS from virus-infected liver. (A) *In vivo* fluorescence imaging day 2 post infection (Ad-CMV-GIRO, 5x10^8 infectious units/mouse). (B) Fluorescence images of PCLS prepared from murine liver at day 2 post infection with Ad-CMV-GIRO (5x10^8 infectious units/mouse). (C) Quantification of fluorescence intensity (radiance) from PCLS (B). (D) H&E staining and immunohistochemistry for cleaved-caspase 3 in PCLS prepared from Ad-CMV-GIRO-infected livers or healthy livers. (E) Mitochondrial stress test of PCLS prepared from Ad-CMV-GIRO-infected livers (5x10^8 infectious units/mouse) or healthy livers. (F) Quantification of caspase 3 activity by luminescence detection assay in PCLS prepared from Ad-CMV-GIRO-infected liver (5x10^8 infectious units/mouse) at 2 h after *ex vivo* TNF challenge (20 ng/ml). (G, H) *Ex vivo* challenge with pharmacological inhibitors of ROS (luteolin), IP_3_ receptor signaling (xestospongin), PLCg-signaling (edelfosin) and TNF (20 ng/ml). (I) *Ex vivo* challenge with pharmacological inhibitors of ROS (luteolin), IP_3_ receptor signaling (xestospongin), PLCg-signaling (edelfosin) and TNF (20 ng/ml). (A–I) Representative data from at least 3 separate experiments are shown as mean ± SEM. Statistical significance was calculated using unpaired t test, *p < 0.05, **p < 0.01 and ***p < 0.001. IP_3_, inositol-3-phosphate; LCMV, lymphocytic choriomeningitis virus; PCLS, precision-cut liver slices; PLCg, phospholipase C gamma; ROS, reactive oxygen species; TNF, tumor necrosis factor.
from virus-infected livers we detected higher caspase 3 activity than in PCLS from uninfected livers at 2 hours after ex vivo TNF challenge (Fig. 2F). Since induction of apoptosis through TNF receptor signaling in virus-infected hepatocytes in vivo requires NADPH-oxidase and generation of reactive oxygen species (ROS), we addressed the question of whether blockade of ROS formation would rescue TNF-induced apoptosis in PCLS. Clearly, incubation of PCLS prepared from Ad-CMV-GIRO infected livers with the ROS-blocking agent luteolin prevented TNF-induced caspase activation (Fig. 2G). To further evaluate the involvement of signaling events downstream of ROS formation, we studied the relevance of phospholipase C gamma (PLCg) activation and inositol-3-phosphate (IP3) receptor signaling for induction of apoptosis in Ad-CMV-GIRO-infected hepatocytes. Incubation with the pharmacological inhibitor of IP3-receptor signaling (xestospongin) prevented TNF-induced caspase 3 activation in PCLS prepared from Ad-CMV-GIRO-infected livers (Fig. 2G). Furthermore, pharmacological inhibition of PLCg-activation with edelfosin equally prevented caspase 3 activation in PCLS prepared from Ad-CMV-GIRO-infected livers at 2 hours after ex vivo TNF challenge (Fig. 2H). To demonstrate that increased sensitivity of hepatocytes to apoptosis in PCLS was not restricted to infection with recombinant adenoviruses, we used the lymphocytic choriomeningitis virus (LCMV) strain WE to infect the liver. PCLS prepared from LCMV-infected livers also showed caspase 3 activation at 2 hours after ex vivo TNF challenge and the extent of liver damage increased with higher TNF doses (Fig. 2I). Together, these results demonstrated that, in PCLS prepared from virus-infected livers ex vivo, a TNF challenge induced caspase 3 activation, which was prevented by inhibition of ROS formation and by interfering with PLCg-activation or IP3-receptor signaling (Fig. 2).

**Discussion**

Studying the response of hepatocytes within their liver microenvironment to signaling processes requires either an in vivo disease model, complex 3D cultures of hepatocytes mimicking the complex liver microenvironment for in vitro studies, or viable liver slice cultures for ex vivo studies. Herein, we demonstrate an improved method for preparation of PCLS that yields liver tissue slices that could be used to characterize ex vivo the hepatocyte-intrinsic response to induction of apoptosis. Improved cutting of liver tissue through immobilization of liver tissue in agarose blocks together with the use of a tissue-preservation solution used in liver transplantation enabled the preparation of PCLS from mouse and human liver tissue that showed almost no procedure-associated cell death. However, PCLS prepared from surgically resected human liver tissue showed few apoptotic cells, which may be related to longer time spans of tissue hypoxia before the start of PCLS preparation. In accordance with this assumption, we did not find a further increase in numbers of apoptotic cells over time after incubation of human PCLS.

Next, we investigated whether PCLS can be used to study liver cell functions ex vivo. Fluorescence activity in hepatocytes infected in vivo with recombinant Ad-CMV-GIRO was preserved ex vivo in PCLS prepared from these livers, which pointed towards conservation of functions of virus-infected hepatocytes. Similarly, mitochondrial respiration was intact in PCLS as determined by extracellular flux analysis of single mouse PCLS, and showed similarity to mitochondrial respiration detected from hepatocytes analyzed ex vivo, which further corroborates that liver cell functionality was maintained in PCLS. Most importantly, development of liver cell death was observed in PCLS prepared from virus-infected livers after TNF challenge ex vivo, which resembled the rapid response of virus-infected hepatocytes to TNF in vivo. Such sensitivity to apoptosis of liver cells in PCLS was not restricted to infection with adenoviruses, a DNA virus, but was also observed after infection with an RNA virus (LCMV) suggesting that the unique sensitivity of hepatocytes to apoptosis after TNF challenge might also be present during infection with other viruses. The development of an improved method to prepare PCLS may therefore allow for the characterization of the underlying mechanism of hepatocyte-intrinsic regulation of apoptosis induction in molecular detail using inhibitors that would exert systemic toxicity in vivo. Furthermore, since we have also shown that human PCLS can be generated with this protocol, PCLS-based analysis of hepatocyte sensitivity to cell death may be extended to human diseases like acute or chronic viral hepatitis, non-alcoholic steatohepatitis or drug-induced liver injury, where liver cell death is observed.

**Abbreviations**

IP3, inositol-3-phosphate; LCMV, lymphocytic choriomeningitis virus; PCLS, precision-cut liver slices; PLCg, phospholipase C gamma; ROS, reactive oxygen species; TNF, tumor necrosis factor.

**Financial support**

German National Science Foundation, SFB TR 179.

**Conflict of interest**

The authors declare no conflict of interest.

Please refer to the accompanying ICMJE disclosure forms for further details.

**Authors’ contributions**

MB, SL, AS, KM, ML performed experiments; NH and DH provided essential study material; MB, ML, KS, DW, PK analyzed the data; MB, SE, PK designed the study; MB, DW and PK wrote the manuscript, all authors approved the manuscript.

**Data availability statement**

The data generated and analyzed are available from the corresponding author, MB, upon reasonable request.

**Acknowledgments**

We thank Silke Hegenbarth, Sava Michailidou, Michaela Müller, Marianne K. Janas (Institute of Molecular Immunology and Experimental Oncology) for technical support.

**Supplementary data**

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jhepr.2022.100465.

**References**

*Author names in bold designate shared co-first authorship.*

[1] Protzer U, Maini MK, Knolle PA. Living in the liver: hepatic infections. Nat Rev Immunol 2012;12:201–213.
[2] Maini MK, Pallett LJ. Defective T-cell immunity in hepatitis B virus infection: why therapeutic vaccination needs a helping hand. Lancet Gastroenterol Hepatol 2018;3:192–202.

[3] Ficht X, Iannacone M. Immune surveillance of the liver by T cells. Sci Immunol 2020;5.

[4] Lampl S, Janas MK, Donakonda S, Brugger M, Lohr K, Schneider A, et al. Reduced mitochondrial resilience enables non-canonical induction of apoptosis after TNF receptor signaling in virus hepatocytes. J Hepatol 2020;73(6):1347–1359.

[5] Wohlleber D, Kashkar H, Gärtner K, Frings MK, Odenthal M, Hegenbarth S, et al. TNF-induced target cell killing by CTL activated through cross-presentation. Cell Rep 2012;2:478–487.

[6] Gebhardt R. Metabolic zonation of the liver: regulation and implications for liver function. Pharmacol Ther 1992;53:275–354.

[7] Gola A, Dorrington MG, Speranza E, Sala C, Shih RM, Radtke AJ, et al. Commensal-driven immune zonation of the liver promotes host defence. Nature 2021;589:131–136.

[8] Godoy P, Hewitt NJ, Albrecht U, Andersen ME, Ansari N, Bhattacharya S, et al. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol 2013;87:1315–1350.

[9] Thanapiprom K, Caen E, Papanetoordi M, Frengueli L, Al-Akkad W, Zhenzhen Z, et al. Optimization and validation of a novel three-dimensional co-culture system in decellularized human liver scaffold for the study of liver fibrosis and cancer. Cancers 2021;13:4936.

[10] Takebe T, Sekine K, Enomura M, Koike H, Kimura M, Ogata T, et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature 2013;499:481–484.

[11] Palma E, Doornebal EJ, Chokshi S. Precision-cut liver slices: a versatile tool to advance liver research. Hepatol Int 2019;13:51–57.

[12] do Graaf IA, Olinga P, de Jager MH, Merema MT, de Kanter R, van de Kerkhof EG, et al. Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies. Nat Protoc 2010;5:1540–1551.

[13] Wu X, Roberto JB, Knupp A, Kenerson HL, Truong CD, Yuen SY, et al. Precision-cut human liver slice cultures as an immunological platform. J Immunol Methods 2018;455:71–79.

[14] Othman A, Ehntert S, Dropmann A, Ruoff M, Nässler AK, Hammad S. Precision-cut liver slices as an alternative method for long-term hepatotoxicity studies. Arch Toxicol 2020;94:2889–2891.

[15] Starokozhko V, Vatakuti S, Schievink B, Merema MT, Asplund A, Synnergren J, et al. Maintenance of drug metabolism and transport functions in human precision-cut liver slices during prolonged incubation for 5 days. Arch Toxicol 2017;91:2079–2092.

[16] van de Bovenkamp M, Groothuis GM, Meijer DK, Olinga P. Liver slices as a model to study fibrogenesis and test the effects of anti-fibrotic drugs on fibrogenic cells in human liver. Toxicol In Vitro 2008;22:771–778.

[17] Graaf IA, Groothuis GM, Olinga P. Precision-cut tissue slices as a tool to predict metabolism of novel drugs. Expert Opin Drug Metab Toxicol 2007;3:875–886.

[18] Hadi M, Westra IM, Starokozhko V, Dragovic S, Merema MT, Groothuis GM. Human precision-cut liver slices as an ex vivo model to study idiosyncratic drug-induced liver injury. Chem Res Toxicol 2013;26:710–720.

[19] Westra IM, Mutsaers HA, Loidl A, Oosterhuis D, de Jong KP, et al. Human precision-cut liver slices as a model to test anti-fibrotic drugs in the early onset of liver fibrosis. Toxicol In Vitro 2015;36:177–85.

[20] Guyot C, Lepreux S, Combe C, Sarrazi V, Billet F, Balbaud C, et al. Fibrogenic cell phenotype modifications during remodelling of normal and pathological human liver in cultured slices. Liver Int 2010;30:1529–1540.

[21] Duryee MJ, Willis MS, Schaffert CS, Reidelberger RD, Dusad A, Anderson DR, et al. Precision-cut liver slices from diet-induced obese rats exposed to ethanol are susceptible to oxidative stress and increased fatty acid synthesis. Am J Physiol Gastrointest Liver Physiol 2014;306:G208–G217.

[22] Sanchez EL, Lagouffo M. Viral activation of cellular metabolism. Virology 2015;479–480:609–618.

[23] Frommel M, Biskup D, Rössle M, Kollmar R, Renn K, et al. Human precision-cut liver slices as a model to test anti-fibrotic drugs in the early onset of liver fibrosis. Toxicol In Vitro 2015;36:177–85.

[24] Khan S, Elham F, Janas MK, Leppert M, Vatakuti S, Schievink B, Merema MT, et al. TNF-induced target cell killing by CTL activated through cross-presentation. Cell Rep 2012;2:478–487.

[25] Godoy P, Hewitt NJ, Albrecht U, Andersen ME, Ansari N, Bhattacharya S, et al. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol 2013;87:1315–1350.

[26] Thanapiprom K, Caen E, Papanetoordi M, Frengueli L, Al-Akkad W, Zhenzhen Z, et al. Optimization and validation of a novel three-dimensional co-culture system in decellularized human liver scaffold for the study of liver fibrosis and cancer. Cancers 2021;13:4936.

[27] Palma E, Doornebal EJ, Chokshi S. Precision-cut liver slices: a versatile tool to advance liver research. Hepatol Int 2019;13:51–57.

[28] do Graaf IA, Olinga P, de Jager MH, Merema MT, de Kanter R, van de Kerkhof EG, et al. Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies. Nat Protoc 2010;5:1540–1551.

[29] Wu X, Roberto JB, Knupp A, Kenerson HL, Truong CD, Yuen SY, et al. Precision-cut human liver slice cultures as an immunological platform. J Immunol Methods 2018;455:71–79.

[30] Othman A, Ehntert S, Dropmann A, Ruoff M, Nässler AK, Hammad S. Precision-cut liver slices as an alternative method for long-term hepatotoxicity studies. Arch Toxicol 2020;94:2889–2891.

[31] Starokozhko V, Vatakuti S, Schievink B, Merema MT, Asplund A, Synnergren J, et al. Maintenance of drug metabolism and transport functions in human precision-cut liver slices during prolonged incubation for 5 days. Arch Toxicol 2017;91:2079–2092.

[32] van de Bovenkamp M, Groothuis GM, Meijer DK, Olinga P. Liver slices as a model to study fibrogenesis and test the effects of anti-fibrotic drugs on fibrogenic cells in human liver. Toxicol In Vitro 2008;22:771–778.

[33] Graaf IA, Groothuis GM, Olinga P. Precision-cut tissue slices as a tool to predict metabolism of novel drugs. Expert Opin Drug Metab Toxicol 2007;3:875–886.

[34] Hadi M, Westra IM, Starokozhko V, Dragovic S, Merema MT, Groothuis GM. Human precision-cut liver slices as an ex vivo model to study idiosyncratic drug-induced liver injury. Chem Res Toxicol 2013;26:710–720.

[35] Westra IM, Mutsaers HA, Loidl A, Oosterhuis D, de Jong KP, et al. Human precision-cut liver slices as a model to test anti-fibrotic drugs in the early onset of liver fibrosis. Toxicol In Vitro 2015;36:177–85.

[36] Guyot C, Lepreux S, Combe C, Sarrazi V, Billet F, Balbaud C, et al. Fibrogenic cell phenotype modifications during remodelling of normal and pathological human liver in cultured slices. Liver Int 2010;30:1529–1540.

[37] Duryee MJ, Willis MS, Schaffert CS, Reidelberger RD, Dusad A, Anderson DR, et al. Precision-cut liver slices from diet-induced obese rats exposed to ethanol are susceptible to oxidative stress and increased fatty acid synthesis. Am J Physiol Gastrointest Liver Physiol 2014;306:G208–G217.

[38] Sanchez EL, Lagouffo M. Viral activation of cellular metabolism. Virology 2015;479–480:609–618.

[39] Frommel M, Biskup D, Rössle M, Kollmar R, Renn K, et al. Human precision-cut liver slices as a model to test anti-fibrotic drugs in the early onset of liver fibrosis. Toxicol In Vitro 2015;36:177–85.

[40] Khan S, Elham F, Janas MK, Leppert M, Vatakuti S, Schievink B, Merema MT, et al. TNF-induced target cell killing by CTL activated through cross-presentation. Cell Rep 2012;2:478–487.